Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class, By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/Subcutaneous, Inhalational), By Region, And Segment Forecasts, 2025 - 2033
The global pulmonary arterial hypertension market size was estimated at USD 8.02 billion in 2024 and is projected to reach USD 13.34 billion by 2033, growing at a CAGR of 5.9% from 2025 to 2033. The market growth is majorly attributed to increasing support from government & healthcare authorities for new drug development, rising prevalence of pulmonary arterial hypertension, and favorable reimbursement policies.
In addition, substantial research and development activities in the field of pulmonary arterial hypertension are also projected to have a positive impact on the market’s growth. For instance, in December 2023, a group of researchers form Cedars-Sinai revealed that unique-cell based approach is well suited for treatment of pulmonary arterial hypertension. Currently, the study in phase I of clinical trials.
The PAH market thrives on significant investments from industry leaders and governments, targeting the unmet needs of this rare condition. Growth is driven by increasing PAH incidence linked to lifestyle factors such as smoking and HIV, alongside aging populations. Government policies, such as the U.S. Orphan Drug Act, incentivize drug development, boosting market expansion. Enhanced diagnostic capabilities and awareness further accelerate demand for effective therapies.
Prostacyclin and analogs, holding 47.11% of 2024 revenue, remain pivotal, with drugs such as epoprostenol and selexipag offers vasodilation benefits. Their ability to improve pulmonary blood flow and patient quality of life underpins their market leadership. Innovations like oral formulations enhance accessibility, and drive segment growth through improved patient adherence.
Sotatercept (Winrevair) has been FDA approved in March 2024 for the treatment of adults with pulmonary arterial hypertension (PAH). It is the first activin signaling inhibitor approved for PAH, shown to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events.
Emerging technologies, such as the Remunity Pump launched in 2021, revolutionize drug delivery, offering subcutaneous treprostinil administration. Digital health tools, including wearables, enable real-time monitoring, personalizing PAH management. These advancements, paired with a strong R&D pipeline, promise to reshape treatment paradigms and sustain market momentum through 2033.
Global Pulmonary Arterial Hypertension Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pulmonary arterial hypertension market report based on drug class, type, route of administration, and region:
In addition, substantial research and development activities in the field of pulmonary arterial hypertension are also projected to have a positive impact on the market’s growth. For instance, in December 2023, a group of researchers form Cedars-Sinai revealed that unique-cell based approach is well suited for treatment of pulmonary arterial hypertension. Currently, the study in phase I of clinical trials.
The PAH market thrives on significant investments from industry leaders and governments, targeting the unmet needs of this rare condition. Growth is driven by increasing PAH incidence linked to lifestyle factors such as smoking and HIV, alongside aging populations. Government policies, such as the U.S. Orphan Drug Act, incentivize drug development, boosting market expansion. Enhanced diagnostic capabilities and awareness further accelerate demand for effective therapies.
Prostacyclin and analogs, holding 47.11% of 2024 revenue, remain pivotal, with drugs such as epoprostenol and selexipag offers vasodilation benefits. Their ability to improve pulmonary blood flow and patient quality of life underpins their market leadership. Innovations like oral formulations enhance accessibility, and drive segment growth through improved patient adherence.
Sotatercept (Winrevair) has been FDA approved in March 2024 for the treatment of adults with pulmonary arterial hypertension (PAH). It is the first activin signaling inhibitor approved for PAH, shown to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events.
Emerging technologies, such as the Remunity Pump launched in 2021, revolutionize drug delivery, offering subcutaneous treprostinil administration. Digital health tools, including wearables, enable real-time monitoring, personalizing PAH management. These advancements, paired with a strong R&D pipeline, promise to reshape treatment paradigms and sustain market momentum through 2033.
Global Pulmonary Arterial Hypertension Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pulmonary arterial hypertension market report based on drug class, type, route of administration, and region:
- Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Branded
- Generics
- Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Oral
- Intravenous/ subcutaneous
- Inhalational
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Rest of LA
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. By Type
1.2.3. Route of Administration
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.9.1. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. PULMONARY ARTERIAL HYPERTENSION MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
CHAPTER 4. PULMONARY ARTERIAL HYPERTENSION MARKET: DRUG CLASS BUSINESS ANALYSIS
4.1. Drug Class Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. Pulmonary Arterial Hypertension Market: Drug Class Movement Analysis, USD Million, 2023 & 2030
4.4. Endothelin Receptor Antagonists (ERAs)
4.4.1. Endothelin Receptor Antagonists (ERAs) Market, 2021 - 2033 (USD Million)
4.5. PDE-5 Inhibitors
4.5.1. PDE-5 Inhibitors Market, 2021 - 2033 (USD Million)
4.6. Prostacyclin and Prostacyclin Analogs
4.6.1. Prostacyclin and Prostacyclin Analogs Market, 2021 - 2033 (USD Million)
4.7. SGC Stimulators
4.7.1. SGC Stimulators Market, 2021 - 2033 (USD Million)
CHAPTER 5. PULMONARY ARTERIAL HYPERTENSION MARKET: TYPE BUSINESS ANALYSIS
5.1. Type Market Share, 2024 & 2033
5.2. Pulmonary Arterial Hypertension Market: Type Movement Analysis, USD Million, 2023 & 2030
5.3. Branded
5.3.1. Branded Market, 2021 - 2033 (USD Million)
5.4. Generic
5.4.1. Generic Market, 2021 - 2033 (USD Million)
CHAPTER 6. PULMONARY ARTERIAL HYPERTENSION MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
6.1. Route of Administration Market Share, 2024 & 2033
6.2. Pulmonary Arterial Hypertension Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
6.3. Oral
6.3.1. Oral Market, 2021 - 2033 (USD Million)
6.4. Intravenous/ Subcutaneous
6.4.1. Intravenous/ Subcutaneous Market, 2021 - 2033 (USD Million)
6.5. Inhalational
6.5.1. Inhalational Market, 2021 - 2033 (USD Million)
CHAPTER 7. REGIONAL BUSINESS ANALYSIS
7.1. Pulmonary Arterial Hypertension Market Share By Region, 2023 & 2030
7.2. North America
7.2.1. North America Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Target Disease Prevalence
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Regulatory Framework
7.2.3.4. Canada Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.2.4. Mexico
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Regulatory Framework
7.2.4.4. Mexico Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3. Europe
7.3.1. Europe Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Regulatory Framework
7.3.2.4. UK Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Regulatory Framework
7.3.3.4. Germany Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Regulatory Framework
7.3.4.4. France Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Regulatory Framework
7.3.5.4. Italy Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Regulatory Framework
7.3.6.4. Spain Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.7. Sweden
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Regulatory Framework
7.3.7.4. Sweden Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.8. Norway
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Regulatory Framework
7.3.8.4. Norway Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.9. Denmark
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Regulatory Framework
7.3.9.4. Denmark Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Japan Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. China Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. India Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Regulatory Framework
7.4.5.4. Australia Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Regulatory Framework
7.4.6.4. Thailand Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Regulatory Framework
7.4.7.4. South Korea Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.5. Latin America
7.5.1. Latin America Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.5.3. Argentina
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. ArgentinaPulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.5.4. Rest of LATAM
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Rest of LATAM Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.6. MEA
7.6.1. MEA Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. South Africa Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Saudi Arabia Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. UAE Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Kuwait Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2023
8.4. Company Profiles/Listing
8.4.1. United Therapeutics Corporation
8.4.1.1. Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Johnson & Johnson Services Inc.
8.4.2.1. Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Bayer AG
8.4.3.1. Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Gilead Sciences, Inc.
8.4.4.1. Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Viatris Inc.
8.4.5.1. Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. GlaxoSmithKline
8.4.6.1. Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Novartis AG
8.4.7.1. Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Lupin Pharmaceuticals Inc.
8.4.8.1. Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Sun Pharmaceutical Industries, Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Teva Pharmaceuticals Industries Ltd.
8.4.10.1. Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. By Type
1.2.3. Route of Administration
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.9.1. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. PULMONARY ARTERIAL HYPERTENSION MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
CHAPTER 4. PULMONARY ARTERIAL HYPERTENSION MARKET: DRUG CLASS BUSINESS ANALYSIS
4.1. Drug Class Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. Pulmonary Arterial Hypertension Market: Drug Class Movement Analysis, USD Million, 2023 & 2030
4.4. Endothelin Receptor Antagonists (ERAs)
4.4.1. Endothelin Receptor Antagonists (ERAs) Market, 2021 - 2033 (USD Million)
4.5. PDE-5 Inhibitors
4.5.1. PDE-5 Inhibitors Market, 2021 - 2033 (USD Million)
4.6. Prostacyclin and Prostacyclin Analogs
4.6.1. Prostacyclin and Prostacyclin Analogs Market, 2021 - 2033 (USD Million)
4.7. SGC Stimulators
4.7.1. SGC Stimulators Market, 2021 - 2033 (USD Million)
CHAPTER 5. PULMONARY ARTERIAL HYPERTENSION MARKET: TYPE BUSINESS ANALYSIS
5.1. Type Market Share, 2024 & 2033
5.2. Pulmonary Arterial Hypertension Market: Type Movement Analysis, USD Million, 2023 & 2030
5.3. Branded
5.3.1. Branded Market, 2021 - 2033 (USD Million)
5.4. Generic
5.4.1. Generic Market, 2021 - 2033 (USD Million)
CHAPTER 6. PULMONARY ARTERIAL HYPERTENSION MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
6.1. Route of Administration Market Share, 2024 & 2033
6.2. Pulmonary Arterial Hypertension Market: Route of Administration Movement Analysis, USD Million, 2023 & 2030
6.3. Oral
6.3.1. Oral Market, 2021 - 2033 (USD Million)
6.4. Intravenous/ Subcutaneous
6.4.1. Intravenous/ Subcutaneous Market, 2021 - 2033 (USD Million)
6.5. Inhalational
6.5.1. Inhalational Market, 2021 - 2033 (USD Million)
CHAPTER 7. REGIONAL BUSINESS ANALYSIS
7.1. Pulmonary Arterial Hypertension Market Share By Region, 2023 & 2030
7.2. North America
7.2.1. North America Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Target Disease Prevalence
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Regulatory Framework
7.2.3.4. Canada Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.2.4. Mexico
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Regulatory Framework
7.2.4.4. Mexico Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3. Europe
7.3.1. Europe Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Regulatory Framework
7.3.2.4. UK Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Regulatory Framework
7.3.3.4. Germany Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Regulatory Framework
7.3.4.4. France Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Regulatory Framework
7.3.5.4. Italy Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Regulatory Framework
7.3.6.4. Spain Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.7. Sweden
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Regulatory Framework
7.3.7.4. Sweden Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.8. Norway
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Regulatory Framework
7.3.8.4. Norway Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.3.9. Denmark
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Regulatory Framework
7.3.9.4. Denmark Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Japan Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. China Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. India Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Regulatory Framework
7.4.5.4. Australia Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Regulatory Framework
7.4.6.4. Thailand Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Regulatory Framework
7.4.7.4. South Korea Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.5. Latin America
7.5.1. Latin America Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.5.3. Argentina
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. ArgentinaPulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.5.4. Rest of LATAM
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Rest of LATAM Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.6. MEA
7.6.1. MEA Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. South Africa Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Saudi Arabia Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. UAE Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Kuwait Pulmonary Arterial Hypertension Market, 2021 - 2033 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2023
8.4. Company Profiles/Listing
8.4.1. United Therapeutics Corporation
8.4.1.1. Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Johnson & Johnson Services Inc.
8.4.2.1. Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Bayer AG
8.4.3.1. Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Gilead Sciences, Inc.
8.4.4.1. Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Viatris Inc.
8.4.5.1. Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. GlaxoSmithKline
8.4.6.1. Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Novartis AG
8.4.7.1. Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Lupin Pharmaceuticals Inc.
8.4.8.1. Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Sun Pharmaceutical Industries, Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Teva Pharmaceuticals Industries Ltd.
8.4.10.1. Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 Average selling prices for approved PAH agents in the U.S. (2023)
Table 3 Summary of pipeline analysis for Early Phase I & Phase I PAH agents
Table 4 Summary of pipeline analysis for Phase II PAH agents
Table 5 Summary of pipeline analysis for Phase III PAH agents
Table 6 Summary of pipeline analysis for Phase IV PAH agents
Table 7 Summary of pipeline analysis for Phase IV PAH agents
Table 8 Global Pulmonary Arterial Hypertension (PAH) market, by Region, 2021 - 2033 ( USD Million)
Table 9 Global Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 10 Global Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 11 Global Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 12 Global Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 13 North America Pulmonary Arterial Hypertension market, by Country, 2021 - 2033 (USD Million)
Table 14 North America Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 15 North America Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 16 North America Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 17 U.S. Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 18 U.S. Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 19 U.S. Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 20 Canada Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 21 Canada Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 22 Canada Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 23 Europe Pulmonary Arterial Hypertension market, by country, 2021 - 2033 (USD Million)
Table 24 Europe Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 25 Europe Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 26 Europe Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 27 UK Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 28 UK Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 29 UK Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 30 Germany Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 31 Germany Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 32 Germany Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 33 France Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 34 France Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 35 France Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 36 Italy Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 37 Italy Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 38 Italy Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 39 Spain Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 40 Spain Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 41 Spain Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 42 Sweden Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 43 Sweden Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 44 Sweden Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 45 Denmark Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 46 Denmark Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 47 Denmark Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 48 Norway Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 49 Norway Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 50 Norway Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 51 Asia Pacific Pulmonary Arterial Hypertension market, by country, 2021 - 2033 (USD Million)
Table 52 Asia Pacific Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 53 Asia Pacific Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 54 Asia Pacific Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 55 China Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 56 China Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 57 China Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 58 Japan Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 59 Japan Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 60 Japan Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 61 India Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 62 India Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 63 India Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 64 Australia Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 65 Australia Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 66 Australia Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 67 South Korea Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 68 South Korea Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 69 South Korea Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 70 Thailand Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 71 Thailand Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 72 Thailand Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 73 Latin America Pulmonary Arterial Hypertension market, by country, 2021 - 2033 (USD Million)
Table 74 Latin America Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 75 Latin America Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 76 Latin America Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 77 Brazil Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 78 Brazil Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 79 Brazil Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 80 Mexico Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 81 Mexico Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 82 Mexico Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 83 Argentina Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 84 Argentina Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 85 Argentina Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 86 MEA Pulmonary Arterial Hypertension market, by Country, 2021 - 2033 (USD Million)
Table 87 MEA Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 88 MEA Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 89 MEA Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 90 South Africa Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 91 South Africa Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 92 South Africa Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 93 Saudi Arabia Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 94 Saudi Arabia Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 95 Saudi Arabia Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 96 UAE Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 97 UAE Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 98 UAE Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 99 Kuwait Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 100 Kuwait Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 101 Kuwait Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 1 List of secondary sources
Table 2 Average selling prices for approved PAH agents in the U.S. (2023)
Table 3 Summary of pipeline analysis for Early Phase I & Phase I PAH agents
Table 4 Summary of pipeline analysis for Phase II PAH agents
Table 5 Summary of pipeline analysis for Phase III PAH agents
Table 6 Summary of pipeline analysis for Phase IV PAH agents
Table 7 Summary of pipeline analysis for Phase IV PAH agents
Table 8 Global Pulmonary Arterial Hypertension (PAH) market, by Region, 2021 - 2033 ( USD Million)
Table 9 Global Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 10 Global Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 11 Global Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 12 Global Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 13 North America Pulmonary Arterial Hypertension market, by Country, 2021 - 2033 (USD Million)
Table 14 North America Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 15 North America Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 16 North America Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 17 U.S. Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 18 U.S. Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 19 U.S. Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 20 Canada Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 21 Canada Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 22 Canada Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 23 Europe Pulmonary Arterial Hypertension market, by country, 2021 - 2033 (USD Million)
Table 24 Europe Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 25 Europe Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 26 Europe Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 27 UK Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 28 UK Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 29 UK Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 30 Germany Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 31 Germany Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 32 Germany Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 33 France Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 34 France Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 35 France Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 36 Italy Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 37 Italy Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 38 Italy Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 39 Spain Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 40 Spain Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 41 Spain Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 42 Sweden Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 43 Sweden Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 44 Sweden Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 45 Denmark Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 46 Denmark Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 47 Denmark Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 48 Norway Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 49 Norway Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 50 Norway Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 51 Asia Pacific Pulmonary Arterial Hypertension market, by country, 2021 - 2033 (USD Million)
Table 52 Asia Pacific Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 53 Asia Pacific Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 54 Asia Pacific Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 55 China Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 56 China Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 57 China Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 58 Japan Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 59 Japan Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 60 Japan Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 61 India Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 62 India Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 63 India Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 64 Australia Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 65 Australia Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 66 Australia Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 67 South Korea Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 68 South Korea Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 69 South Korea Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 70 Thailand Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 71 Thailand Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 72 Thailand Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 73 Latin America Pulmonary Arterial Hypertension market, by country, 2021 - 2033 (USD Million)
Table 74 Latin America Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 75 Latin America Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 76 Latin America Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 77 Brazil Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 78 Brazil Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 79 Brazil Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 80 Mexico Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 81 Mexico Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 82 Mexico Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 83 Argentina Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 84 Argentina Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 85 Argentina Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 86 MEA Pulmonary Arterial Hypertension market, by Country, 2021 - 2033 (USD Million)
Table 87 MEA Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 88 MEA Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 89 MEA Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 90 South Africa Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 91 South Africa Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 92 South Africa Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 93 Saudi Arabia Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 94 Saudi Arabia Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 95 Saudi Arabia Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 96 UAE Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 97 UAE Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 98 UAE Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
Table 99 Kuwait Pulmonary Arterial Hypertension market, by Type, 2021 - 2033 (USD Million)
Table 100 Kuwait Pulmonary Arterial Hypertension market, by Route of Administration, 2021 - 2033 (USD Million)
Table 101 Kuwait Pulmonary Arterial Hypertension market, by Drug Class, 2021 - 2033 (USD Million)
LIST OF FIGURES
Fig. 1 Pulmonary Arterial Hypertension market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Pulmonary Arterial Hypertension market dynamics
Fig. 12 Pulmonary Arterial Hypertension market Porter’s five forces analysis
Fig. 13 Pulmonary Arterial Hypertension market PESTLE analysis
Fig. 14 Drug Class market, 2021 - 2033 (USD Million)
Fig. 15 Endothelin Receptor Antagonists (ERAs) market, 2021 - 2033 (USD Million)
Fig. 16 PDE-5 Inhibitors market, 2021 - 2033 (USD Million)
Fig. 17 Prostacyclin and Prostacyclin Analogs market, 2021 - 2033 (USD Million)
Fig. 18 SGC Stimulators market, 2021 - 2033 (USD Million)
Fig. 19 Type market, 2021 - 2033 (USD Million)
Fig. 20 Branded market, 2021 - 2033 (USD Million)
Fig. 21 Generics market, 2021 - 2033 (USD Million)
Fig. 22 Route of Administration market, 2021 - 2033 (USD Million)
Fig. 23 Oral market, 2021 - 2033 (USD Million)
Fig. 24 Intravenous/ Subcutaneous market, 2021 - 2033 (USD Million)
Fig. 25 Inhalational market, 2021 - 2033 (USD Million)
Fig. 26 Pulmonary Arterial Hypertension market revenue, by region
Fig. 27 Regional marketplace Key takeaways
Fig. 28 North America pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 29 U.S. country dynamics
Fig. 30 U.S. pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 31 Canada country dynamics
Fig. 32 Canada pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 33 Mexico country dynamics
Fig. 34 Mexico pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 35 Europe pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 36 UK country dynamics
Fig. 37 UK pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 38 Germany country dynamics
Fig. 39 Germany pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 40 France country dynamics
Fig. 41 France pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 42 Italy country dynamics
Fig. 43 Italy pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 44 Spain country dynamics
Fig. 45 Spain pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 46 Norway country dynamics
Fig. 47 Norway pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 48 Sweden country dynamics
Fig. 49 Sweden pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 50 Denmark country dynamics
Fig. 51 Denmark pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 52 Asia Pacific pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 53 Japan country dynamics
Fig. 54 Japan pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 55 China country dynamics
Fig. 56 China pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 57 India country dynamics
Fig. 58 India pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 59 Australia country dynamics
Fig. 60 Australia pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 61 South Korea country dynamics
Fig. 62 South Korea pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 63 Thailand country dynamics
Fig. 64 Thailand pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 65 Latin America pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 66 Brazil country dynamics
Fig. 67 Brazil pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 68 Argentina country dynamics
Fig. 69 Argentina pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 70 MEA pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 71 South Africa country dynamics
Fig. 72 South Africa pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 73 Saudi Arabia country dynamics
Fig. 74 Saudi Arabia pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 75 UAE country dynamics
Fig. 76 UAE pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 77 Kuwait country dynamics
Fig. 78 Kuwait pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 79 Company categorization
Fig. 80 Company market position analysis
Fig. 81 Strategic framework
Fig. 1 Pulmonary Arterial Hypertension market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Pulmonary Arterial Hypertension market dynamics
Fig. 12 Pulmonary Arterial Hypertension market Porter’s five forces analysis
Fig. 13 Pulmonary Arterial Hypertension market PESTLE analysis
Fig. 14 Drug Class market, 2021 - 2033 (USD Million)
Fig. 15 Endothelin Receptor Antagonists (ERAs) market, 2021 - 2033 (USD Million)
Fig. 16 PDE-5 Inhibitors market, 2021 - 2033 (USD Million)
Fig. 17 Prostacyclin and Prostacyclin Analogs market, 2021 - 2033 (USD Million)
Fig. 18 SGC Stimulators market, 2021 - 2033 (USD Million)
Fig. 19 Type market, 2021 - 2033 (USD Million)
Fig. 20 Branded market, 2021 - 2033 (USD Million)
Fig. 21 Generics market, 2021 - 2033 (USD Million)
Fig. 22 Route of Administration market, 2021 - 2033 (USD Million)
Fig. 23 Oral market, 2021 - 2033 (USD Million)
Fig. 24 Intravenous/ Subcutaneous market, 2021 - 2033 (USD Million)
Fig. 25 Inhalational market, 2021 - 2033 (USD Million)
Fig. 26 Pulmonary Arterial Hypertension market revenue, by region
Fig. 27 Regional marketplace Key takeaways
Fig. 28 North America pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 29 U.S. country dynamics
Fig. 30 U.S. pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 31 Canada country dynamics
Fig. 32 Canada pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 33 Mexico country dynamics
Fig. 34 Mexico pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 35 Europe pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 36 UK country dynamics
Fig. 37 UK pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 38 Germany country dynamics
Fig. 39 Germany pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 40 France country dynamics
Fig. 41 France pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 42 Italy country dynamics
Fig. 43 Italy pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 44 Spain country dynamics
Fig. 45 Spain pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 46 Norway country dynamics
Fig. 47 Norway pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 48 Sweden country dynamics
Fig. 49 Sweden pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 50 Denmark country dynamics
Fig. 51 Denmark pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 52 Asia Pacific pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 53 Japan country dynamics
Fig. 54 Japan pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 55 China country dynamics
Fig. 56 China pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 57 India country dynamics
Fig. 58 India pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 59 Australia country dynamics
Fig. 60 Australia pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 61 South Korea country dynamics
Fig. 62 South Korea pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 63 Thailand country dynamics
Fig. 64 Thailand pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 65 Latin America pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 66 Brazil country dynamics
Fig. 67 Brazil pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 68 Argentina country dynamics
Fig. 69 Argentina pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 70 MEA pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 71 South Africa country dynamics
Fig. 72 South Africa pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 73 Saudi Arabia country dynamics
Fig. 74 Saudi Arabia pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 75 UAE country dynamics
Fig. 76 UAE pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 77 Kuwait country dynamics
Fig. 78 Kuwait pulmonary arterial hypertension market, 2021 - 2033 (USD Million)
Fig. 79 Company categorization
Fig. 80 Company market position analysis
Fig. 81 Strategic framework
